ELCELYX THERAPEUTICS
Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic... market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets. Elcelyx is headquartered in San Diego, California.
ELCELYX THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2010-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.elcelyx.com
Total Employee:
11+
Status:
Active
Contact:
(858) 876-1814
Total Funding:
96.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud Pound Sterling OpenResty
Current Advisors List
Board_member
Board_member
Board_member
Founder
Investors List
Clough Capital Partners
Clough Capital Partners investment in Series E - Elcelyx Therapeutics
Morgenthaler Ventures
Morgenthaler Ventures investment in Series E - Elcelyx Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series E - Elcelyx Therapeutics
Technology Partners
Technology Partners investment in Series E - Elcelyx Therapeutics
Sailing Capital
Sailing Capital investment in Series E - Elcelyx Therapeutics
Kleiner Perkins
Kleiner Perkins investment in Series E - Elcelyx Therapeutics
GSM Fund
GSM Fund investment in Series E - Elcelyx Therapeutics
Kleiner Perkins
Kleiner Perkins investment in Series C - Elcelyx Therapeutics
Technology Partners
Technology Partners investment in Series C - Elcelyx Therapeutics
Morgenthaler Ventures
Morgenthaler Ventures investment in Series C - Elcelyx Therapeutics
Official Site Inspections
http://www.elcelyx.com
- Host name: 104.21.81.175
- IP address: 104.21.81.175
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Elcelyx Therapeutics"
Elcelyx Therapeutics - Crunchbase Company Profile & Funding
Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered …See details»
Elcelyx Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Elcelyx Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 1 news, and 4 literature, Drug:Metformin. ... The statistics for drugs in the …See details»
Elcelyx Company Profile 2024: Valuation, Funding
Elcelyx General Information Description. Developer of nutrient based products designed to treat diabetes, weight management and obesity-related metabolic disorders. The company's products include Lovidia(TM) and NewMet(TM) …See details»
Elcelyx Therapeutics Inc. - LinkedIn
Elcelyx (“L-cell-ix”) was founded in 2010 to advance Gut Sensory Modulation (GSM) technology, based on the elucidation that enteroendocrine cells located in the lining of the lower gut can be ...See details»
ELCELYX THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ELCELYX THERAPEUTICS, INC. of San Diego, CA. Get the latest business insights from Dun & …See details»
Elcelyx Therapeutics Inc - Company Profile and News
Company profile page for Elcelyx Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Elcelyx Therapeutics - Craft
Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The …See details»
Elcelyx Therapeutics - Funding, Financials, Valuation & Investors
Elcelyx Therapeutics is funded by 7 investors. Clough Capital Partners and Morgenthaler Ventures are the most recent investors. Elcelyx Therapeutics has a post-money valuation in …See details»
Elcelyx Therapeutics - VentureRadar
" Elcelyx Therapeutics is developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of …See details»
Elcelyx Therapeutics - Products, Competitors, Financials, …
Elcelyx Therapeutics is developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones …See details»
Elcelyx Therapeutics - Contacts, Employees, Board Members
Organization. Elcelyx Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Number of Board Member and …See details»
Elcelyx Therapeutics Company Profile: Overview and Full News …
Elcelyx Therapeutics is also actively involved in the development of other therapeutic candidates targeting metabolic diseases, leveraging their expertise in gut modulation and metabolic …See details»
Elcelyx Therapeutics CEO and Key Executive Team | Craft.co
Elcelyx Therapeutics's President and CEO, Director is Alain D. Baron. Other executives include Jay Sherwood, CFO; Mark Fineman, Chief Scientific Officer and 1 others. See the full …See details»
Elcelyx raises $40M to push its reinvented diabetes drug to Phase III
Oct 1, 2015 Elcelyx Therapeutics, developing a long-acting formulation of the old diabetes treatment metformin, closed a $40 million funding round to advance its lead therapy toward …See details»
Anji Pharmaceuticals Acquires Late-Stage Clinical Asset and …
May 29, 2019 Elcelyx Therapeutics is developing pharmaceutical agents designed to modulate the gut neuroendocrine system including the L-cell, which when activated is responsible for …See details»
Elcelyx Therapeutics Announces $40 Million Series E Financing
Oct 1, 2015 Company Enrolling Phase 2b Trial of Metformin Delayed Release for Type 2 Diabetes SAN DIEGO, Oct. 1, 2015 – Elcelyx Therapeutics has raised $40 million in a Series …See details»
Alain D. Baron - Crunchbase Person Profile
Alain Baron was named President and CEO of Elcelyx Therapeutics in 2010. Prior to Elcelyx, Dr. Baron was an Entrepreneur-in-Residence and a member of the Life Science Team at …See details»
Anji Pharma nabs $70M for late-stage diabetes treatment, ex …
Sep 28, 2021 Anji is advancing the asset after snagging it from Elcelyx, which conducted a phase 2b study with 571 patients prior to selling it in May 2019. The phase 3 trial will be …See details»
Anji Pharma nabs $70M for late-stage diabetes treatment, ex …
Oct 5, 2021 Anji is advancing the asset after snagging it from Elcelyx, which conducted a phase 2b study with 571 patients prior to selling it in May 2019. The phase 3 trial will be expanded to …See details»
Elcelyx Therapeutics closes enrolment in Phase llb trial of …
May 25, 2016 Elcelyx noted that even though metformin is the preferred agent to treat type 2 diabetes, patients often discontinue it due to renal impairment and gastrointestinal intolerance. …See details»